{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:10:19Z","timestamp":1699960219261},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T00:00:00Z","timestamp":1178668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Rapid resolution of symptoms is a priority for clinicians treating acute psychosis, and rapid initiation of pharmacotherapy may prove beneficial. This study examined rapid dose initiation of quetiapine in acutely ill patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 2\u2010week, multicentre, randomised, parallel\u2010group, open study. Inpatients (<jats:italic>n<\/jats:italic>\u2009=\u2009269) diagnosed with schizophrenia or schizoaffective disorder received rapid (<jats:italic>n<\/jats:italic>\u2009=\u2009139) or conventional (<jats:italic>n<\/jats:italic>\u2009=\u2009130) initiation of quetiapine, followed by flexible dosing (maximum 800\u2009mg\/day). Primary outcome included proportion of patients experiencing \u22651 episode of selected AEs (somnolence, dizziness, orthostatic hypotension) during Week 1. Secondary outcomes included discontinuations due to AEs, and efficacy assessed by BPRS and CGI\u2010S scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The proportion of patients with \u22651 selected AE during Week 1 was 5.4% and 10.1% in the conventional and rapid initiation groups, respectively. Most common AEs (&gt;5% patients) were hypotension, tachycardia, somnolence and sedation. Overall, four (3.1%) and three (2.1%) patients from the conventional and rapid initiation group, respectively, withdrew due to AEs. BPRS and CGI\u2010S scores decreased significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) from baseline in both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A higher proportion of patients experienced AEs with rapid initiation of quetiapine (800\u2009mg\/day by Day 4), although withdrawals due to AEs were comparable. Rapid initiation of quetiapine was generally well tolerated and effective in this setting. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.844","type":"journal-article","created":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T10:23:52Z","timestamp":1178706232000},"page":"299-306","source":"Crossref","is-referenced-by-count":14,"title":["Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel\u2010group, open study"],"prefix":"10.1002","volume":"22","author":[{"given":"Giuseppina","family":"Boidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,9]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"American Psychiatric Association.2004.Practice guideline for the treatment of patients with schizophrenia. Available atwww.psych.org(accessed 15 August 2005)."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003430"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"e_1_2_1_5_1","unstructured":"AstraZeneca.2005.Seroquel\u00ae (quetiapine fumarate) tablets\/US prescribing information. Available athttp:\/\/www.astrazeneca\u2010us.com\/pi\/Seroquel.pdf(accessed 1 June 2006)."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565090-00003"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1116g"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199604000-00008"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125004510"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80094-2"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2007.58.1.11"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1203"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799001476"},{"issue":"14","key":"e_1_2_1_14_1","first-page":"21","article-title":"Atypical antipsychotic medications in the psychiatric emergency service","volume":"61","author":"Currier GW","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200601000-00005"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85018-4"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500510029011"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500600579068"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050603"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2004.02.021"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418090-00005"},{"issue":"11","key":"e_1_2_1_22_1","first-page":"8","article-title":"Expert consensus guideline series. Treatment of schizophrenia 1999","volume":"60","author":"McEvoy JP","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651509709024734"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(05)81051-X"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056665"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10162.x"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000168486.14516.7c"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500510029192"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.844","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:38:38Z","timestamp":1699958318000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["10.1002\/hup.844"],"URL":"https:\/\/doi.org\/10.1002\/hup.844","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,9]]}}}